SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2017 / Cilt: 47 - Sayı: 3

Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia

Proliferatif Tip 2 İdiyopatik Jukstafoveal Telenjiektazi Tedavisinde İntravitreal Bevacizumabın Etkinliği

Ali DEMİRCAN
Irfan PERENTE
Muhittin TAŞKAPILI
Ihsan YİLMAZ
Abdullah ÖZKAYA
Cengiz ALAGÖZ
Ökkeş BAZ
Pages
144–148
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: IVB treatment may be effective in the treatment of subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the effectiveness of intravitreal bevacizumab (IVB) in patients with subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.
📊
Key Findings & Data:Materials and Methods: Ten eyes of 10 patients were included in this retrospective study.
💡
Conclusion & Impact:Conclusion: IVB treatment may be effective in the treatment of subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the effectiveness of intravitreal bevacizumab (IVB) in patients with subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia. Materials and Methods: Ten eyes of 10 patients were included in this retrospective study. All cases were treated with IVB (1.25 mg bevacizumab). Visual acuity and slit-lamp anterior and posterior segment examinations were performed at each visit. Central macular thickness (CMT) and intraretinal/subretinal fluid were evaluated via spectral domain optical coherence tomography (OCT). Loss of a line in visual acuity chart and presence of fluid on OCT were defined as criteria for repeated treatment. Results: The mean age of patients was 66.0±7.0 years (56-75). The mean follow-up time was 54.7±16.0 month (24-72). The mean BCVA was 0.62±0.35 (0.00-1.00) logMAR at baseline and 0.54±0.35 (0.00-1.00) logMAR at final exam (p=0.03). The mean CMT was 251±25.4 μm at baseline and 239±39.3 μm at final exam (p=0.01). Patients received an average of 1.7±1.0 IVB injections during follow-up. At baseline, all cases had intraretinal/subretinal fluid. There was no fluid at final examination of all cases. Conclusion: IVB treatment may be effective in the treatment of subretinal neovascularization secondary to type 2 juxtafoveal telangiectasia.

Özet

Amaç: Tip 2 jukstafoveal telenjiektazi’ye (JFT) bağlı subretinal neovaskülarizasyon (SRNV) tedavisinde intravitreal bevacizumab (İVB)etkinliğini araştırmak.Gereç ve Yöntem: Retrospektif olarak planlanan çalışmaya tip 2 JFT’li 10 hastanın 10 gözü alındı. Hastaların tamamı İVB (1,25mg bevacizumab) ile tedavi edildi. Hastaların her kontrolde görme keskinliği alınıp, biyomikroskopik ön segment ve fundus muayenesiyapıldı. Spektral optik kohorens tomografi (S-OKT) ile merkezi maküla kalınlığı (MMK) ve retina altı/retina içi sıvı mevcudiyetideğerlendirildi. Görme keskinliğinde 1 sıra ve üzeri azalma, S-OKT’de sıvı mevcudiyeti yeni tedavi kriteri olarak belirlendi.Bulgular: Hastaların yaş ortalaması 66±7,0 (56-75) idi. Ortalama takip süresi 54,7±16 (24-72) aydı. Tedavi öncesi ortalama en iyidüzeltilmiş görme keskinliği 0,62±0,35 (0,00-1,00) logMAR iken, son kontrolde 0,54±0,35 (0,00-1,00) logMAR seviyesinde idi(p=0,03). Tedavi öncesi MMK 251±25,4 μm iken, son kontrolde 239±39,3 μm olarak tespit edilidi (p=0,01). Hastalara ortalama takipsüresi boyunca ortalama 1,7±1,0 İVB enjeksiyonu uygulandı. Enjeksiyon öncesi olguların tamamında retina içi/retina altı sıvı mevcuttu.Son kontrolde hiçbir hastada OKT’de retina altı/retina içi sıvı görülmedi.Sonuç: Tip 2 JFT’ye bağlı SRNV tedavisinde intravitreal İVB uygulaması görme keskinliğinin korunmasında ve maküler ödemingeriletilmesinde etkili görülmektedir.

🔖

Cite This Article

DEMİRCAN, A., PERENTE, I., TAŞKAPILI, M., YİLMAZ, I., ÖZKAYA, A., ALAGÖZ, C., BAZ, Ö. (2022). Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia. Türk Oftalmoloji Dergisi, Cilt: 47 - Sayı: 3, 144–148. https://ajindex.com/articles/637884

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Karagiannis D, Georgalas I, Ladas I, Eustratios P, Mitropoulos P. A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin Interv Aging. 2009;4:63-65.
  2. Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina. 2011;31:1848-1855.
  3. Jorge R, Costa RA, Calucci D, Scott IU. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol. 2007;245:1045-1048.
  4. Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, Pappuru RR, Kuppermann BD. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina. 2012;32:2001-2005.
  5. Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2007;245:1825- 1829. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157-160.
  6. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
  7. Engelbrecht NE, Aaberg TM Jr, Sung J, Lewis ML. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol. 2002;120:320-324.
  8. Narayanan R, Majji AB, Hussain N, Hussain A, Jalali S, Mathai A, Shah VA. Characterization of idiopathic macular telangiectasia type 2 by fundus fluorescein angiography in Indian population. Eur J Ophthalmol. 2008;18:587-590.
  9. Takayama K, Ooto S, Tamura H, Yamashiro K, Otani A, Tsujikawa A, Yoshimura N. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye (Lond). 2010;24:1492-1497.
  10. Matsumoto Y, Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol. 2010;54:320-324.
  11. Kovach JL, Rosenfeld PJ. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina. 2009;29:27-32.
  12. Charbel Issa P, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coher